Risk Factors and Real-World Implications of CMV Resistance Mutations After Treatment with Maribavir or Foscarnet for Resistant and Refractory CMV
2025 · American Journal of Transplantation · 0 citations
https://doi.org/10.1016/j.ajt.2025.07.068
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
3
Papers
7
Citations
1
h-index
0
i10-index
Chelsea Morinishi is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Cytomegalovirus and herpesvirus research & Herpesvirus Infections and Treatments & Viral Infections and Immunology Research. The author has an h-index of 1, co-authored 3 publications.
ORCID: 0000-0002-9967-5766Click to start Chat